Alnylam announces new positive results from Phase 1/2 study of lumasiran in...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting...
View ArticleAlnylam’s patisiran receives positive opinion from CHMP for treating hATTR...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the Committee for Medicinal Products for Human Use has adopted a Positive Opinion recommending marketing...
View ArticleEC grants marketing authorization for ONPATTRO (patisiran) in Europe
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO (patisiran) for the treatment of...
View ArticleAlnylam announces positive results from Phase 3 Study of givosiran for...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational...
View ArticleAlnylam reports further progress on broadening the therapeutic potential of RNAi
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including...
View ArticleAlnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products...
View ArticleAlnylam announces positive results from Phase 1/2 study of lumasiran for...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously...
View ArticleRBSC announces partnership with Mitacs to develop and test yeast-based RNAi...
Renaissance BioScience Corp., a leading global microorganism bioengineering company, is pleased to announce a new partnership with Mitacs, the University of British Columbia and the University of...
View ArticleApplication of various nanoparticle-capsulated siRNA as therapeutics for...
In a review published in the International Journal of Molecular Sciences, researchers have been reviewing the use of siRNAs to target coronaviruses.
View Article